pdf   xlsx method abbreviations

mNSCLC - L1 - TMB>10Mb, immune chekpoint inhibitors , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

progression or deaths (PFS) 0.58 [0.41, 0.82]< 10%1 study (1/-)99.9 %NAnot evaluable important-
objective responses (ORR) 2.26 [1.39, 3.66]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

STRAE (any grade) 2.67 [1.51, 4.74]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
STRAE (grade 3-4) 2.19 [1.14, 4.20]< 10%1 study (1/-)0.9 %NAnot evaluable non important-
TRAE (any grade) 1.28 [0.71, 2.30]< 10%1 study (1/-)21.0 %NAnot evaluable non important-
TRAE (grade 3-4) 1.02 [0.64, 1.65]< 10%1 study (1/-)46.1 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 3.49 [1.78, 6.83]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE leading to discontinuation (grade 3-4) 2.90 [1.32, 6.37]< 10%1 study (1/-)0.4 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Anaemia TRAE (grade 3-4) 0.26 [0.07, 0.92]< 10%1 study (1/-)98.2 %NAnot evaluable non important-
Asthenia TRAE (grade 3-4) 1.18 [0.23, 5.95]< 10%1 study (1/-)42.0 %NAnot evaluable non important-
Constipation TRAE (grade 3-4) 0.59 [0.02, 17.65]< 10%1 study (1/-)61.9 %NAnot evaluable non important-
Decreased appetite TRAE (grade 3-4) 0.29 [0.03, 2.62]< 10%1 study (1/-)86.4 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 1.78 [0.29, 10.84]< 10%1 study (1/-)26.6 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 0.29 [0.03, 2.62]< 10%1 study (1/-)86.4 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 1.18 [0.02, 59.79]< 10%1 study (1/-)46.8 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 1.18 [0.16, 8.49]< 10%1 study (1/-)43.5 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 0.03 [0.00, 0.46]< 10%1 study (1/-)99.3 %NAnot evaluable non important-
Pruritus TRAE (grade 3-4) 4.77 [0.21, 106.62]< 10%1 study (1/-)16.5 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 7.20 [0.36, 145.12]< 10%1 study (1/-)10.1 %NAnot evaluable non important-
Vomiting TRAE (grade 3-4) 0.19 [0.02, 1.60]< 10%1 study (1/-)93.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons